AMAG - AMAG Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

AMAG Pharmaceuticals, Inc.

1100 Winter Street
Waltham, MA 02451
United States
617-498-3300
http://www.amagpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees762

Key Executives

NameTitlePayExercisedYear Born
Dr. William K. HeidenCEO, Pres & Director1.18MN/A1960
Mr. Edward H. MylesExec. VP & CFO434.9kN/A1972
Mr. Joseph D. VittiglioExec. VP of Legal Affairs and Quality, Gen. Counsel & Sec.528.06kN/A1972
Dr. Julie KropExec. VP of Devel. & Chief Medical Officer567.37kN/A1966
Mr. Nicholas GrundExec. VP & Chief Commercial Officer772.39kN/A1970
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

AMAG Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.